Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Ovarian Neoplasms 2Solid Tumors 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma 1Neuroectodermal Tumors 1Nervous System Diseases 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Head and Neck Neoplasms 1HER2-negative Breast Cancer 1Gliosarcoma 1Glioblastoma 1For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment 1Esophageal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Astrocytoma 1Advanced Malignancies 1

Interventions

pembrolizumab 72Cisplatin 57Cetuximab 38Fluorouracil 25Nivolumab 21Radiotherapy 20Carboplatin 19Paclitaxel 14Docetaxel 11Cyclophosphamide 9Gefitinib 8fludarabine 7durvalumab 7zalutumumab 6atezolizumab 6Drug Therapy 6Bleomycin 6epacadostat 5cemiplimab 5Radiotherapy, Intensity-Modulated 5Pemetrexed 5Ipilimumab 5Gemcitabine 5Afatinib 5spartalizumab 4Standard of Care 4Radiation 4Injections 4Immune Checkpoint Inhibitors 4Fibroblast Growth Factor 7 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Head and Neck Neoplasms × pamiparib × Clear all
NCT03150810 2024-12-20

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

BeiGene

Phase 1 Completed
139 enrolled 36 charts
BreastGastrointestinalGynecologicHead & NeckSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡